Clinical trials: Hepatic Chemotherapy
Hepatocellular Carcinoma
Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection
To study if the addition of HAIC following complete removal of early stage liver cancer of HCC will prevent or delay the recurrence of the disease.
- Trial name
- HAICAT (NCT02767375)
- Testing
- Oxaliplatin(OXA), 5-fluorouracil (5-FU), Hepatic arterial catheter implantation
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Atezolizumab plus bevacizumab is the first-line treatment for patients with advanced hepatocellular carcinoma. However, the prognosis for high-risk hepatocellular carcinoma is still poor, with a median overall survival of 7.6…
- Trial name
- NCT05886465
- Testing
- Atezolizumab, Bevacizumab, HAIC with FOLFOX
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC), Emotional Distress
Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
This study is a multicenter, prospective, observational clinical trial designed to evaluate the impact of baseline emotional status on the clinical outcomes of patients with BCLC stage B/C hepatocellular carcinoma undergoing HAIC…
- Conditions
- Hepatocellular Carcinoma (HCC), Emotional Distress, HAIC(Hepatic Artery Infusion Chemotherapy), Immunotherapy
- Trial name
- NCT07436845
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Potentially Resectable Hepatocellular Carcinoma
Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.
- Trial name
- NCT06796803
- Testing
- camrelizumab combined with rivoceranib and HAIC, camerlizumab + rivoceranib
- Where
- 2 sites in China
- Volunteers
- 398 people
- Sponsor
- Shanghai Zhongshan Hospital
Melanoma, Uveal Neoplasms
The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases
A randomized controlled, open-label, multi-centre study evaluating if Isolated Hepatic Perfusion (IHP) increases Overall Survival compared with Best Alternative Care (BAC) in patients with isolated liver metastases from uveal…
- Trial name
- SCANDIUM (NCT01785316)
- Testing
- IHP
- Where
- Sweden
- Volunteers
- 93 people
- Sponsor
- Vastra Gotaland Region
Histologically-proven and Radiologically-confirmed Solid Tumors
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function
This study is designed to obtain pharmacokinetic data following a single-dose 20-minute i.v. administration of ASA404 (900, 1200, or 1800 mg/m2) in adult cancer patients with varying degrees of hepatic impairment.
- Trial name
- NCT01278849
- Testing
- ASA404
- Where
- 4 sites in Italy, New Zealand
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Liver Metastases (CRCLM)
To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases
Both drug-eluting bead transarterial chemoembolization (DEB-TACE) and hepatic arterial infusion chemotherapy (HAIC) are recommended for unresectable colorectal liver metastases (CRLM) treatment.
- Trial name
- NCT05889325
- Testing
- DEB-TACE plus HAIC
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma, Hepatic Chemotherapy
TACE Combined Surgery for the Resectable Huge HCC
Huge hepatocellular carcinoma (HCC) is defined as a tumor with a maximum diameter greater than 10 cm. With advancements in surgical techniques, hepatectomy can be performed safely in some patients with huge HCC without vascular…
- Conditions
- Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery
- Trial name
- NCT06898398
- Testing
- TACE, Surgery
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Sun Yat-sen University
Cholangiocarcinoma
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma
A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine in combination with cetuximab in patient with non-resectable liver metastases…
- Trial name
- NCT01247337
- Testing
- Oxaliplatin, capecitabine, gemcitabine, cetuximab, Oxaliplatin, capecitabine, gemcitabine cetuximab
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Dorte Nielsen
Unresectable Intrahepatic Cholangiocarcinoma
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC.
- Trial name
- NCT02994251
- Testing
- gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Colorectal Cancer Metastatic
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
This prospective, randomized, controlled clinical study aims to evaluate the objective remission rate of FOLFOX hepatic artery infusion chemotherapy (HAI) in combination with systemic irinotecan with or without bevacizumab versus…
- Trial name
- NCT05727163
- Testing
- Dexamethasone, Anisodamine, Oxaliplatin
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Sun Yat-sen University
Malignant Tumor of Pancreas Metastatic to Liver
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
This study is a randomized open-label phase 2b study of the efficacy and safety of regional infusion therapy with Anti-CEA CAR-T cells using the hepatic immunotherapy for metastases (HITM) method and the Trisalus pressure…
- Trial name
- NCT04037241
- Testing
- Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA
- Sponsor
- Sorrento Therapeutics, Inc.
Hepatocellular Carcinoma
Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with advanced…
- Trial name
- NCT03812770
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 3 sites in China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Metastatic Cancer
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Trial name
- NCT00020501
- Testing
- FOLFIRI regimen, floxuridine, fluorouracil
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma, Chemotherapy Effect
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
The goal of this clinical trial is to compare HAIC concurrently with sequentially combined with targeted and immunotherapies in terms of efficacy and safety in patients with potentially resectable intermediate and advanced HCC…
- Conditions
- Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- HAIC (NCT06041477)
- Testing
- Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Concurrent Lenvatinib, Concurrent PD-1 antibody
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
Renal Impairment, Hepatic Impairment
Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment
The purpose of this study is to examine the effects of renal and hepatic impairment on TAK-272 pharmacokinetics with a single oral administration of TAK-272 in participants with renal or hepatic impairment.
- Trial name
- NCT02367872
- Testing
- TAK-272
- Where
- 4 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Takeda
Liver Cancer
HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC
Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
- Trial name
- FRONT-1 (NCT05532319)
- Testing
- HAIC sequential TAE combined with lenvatinib and tislelizumab
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Guangxi Medical University
Colorectal Cancer
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
The objective of this clinical trial is to evaluate the efficacy and safety of combining fruquintinib with hepatic artery infusion (HAI)-FOLFOX in the treatment of refractory colorectal cancer with liver metastasis.
- Trial name
- NCT06441565
- Testing
- Fruquintinib, Fluorouracil, Oxaliplatin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread…
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
- Trial name
- NCT05863195
- Testing
- Bevacizumab, Capecitabine, Cetuximab
- Where
- 62 sites in United States
- Volunteers
- 408 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Hepatic Cancer, Metastatic Cancer
Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors
In the structure of malignant liver lesions, two main groups are distinguished - primary liver cancer and metastatic liver damage. The five-year survival rate of patients with malignant liver tumors does not exceed 6%.
- Conditions
- Hepatic Cancer, Metastatic Cancer, Chemotherapy Effect
- Trial name
- PATOC (NCT04764409)
- Testing
- Chemoembolization, Chemoinfusion
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- Central Clinical Hospital RZD-Medicine, Russian Federation